JP2008517059A5 - - Google Patents

Download PDF

Info

Publication number
JP2008517059A5
JP2008517059A5 JP2007537944A JP2007537944A JP2008517059A5 JP 2008517059 A5 JP2008517059 A5 JP 2008517059A5 JP 2007537944 A JP2007537944 A JP 2007537944A JP 2007537944 A JP2007537944 A JP 2007537944A JP 2008517059 A5 JP2008517059 A5 JP 2008517059A5
Authority
JP
Japan
Prior art keywords
colitis
pharmaceutically acceptable
pharmaceutical composition
inflammatory bowel
bowel disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007537944A
Other languages
English (en)
Other versions
JP2008517059A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/037161 external-priority patent/WO2006044741A1/en
Publication of JP2008517059A publication Critical patent/JP2008517059A/ja
Publication of JP2008517059A5 publication Critical patent/JP2008517059A5/ja
Abandoned legal-status Critical Current

Links

Claims (2)

  1. 式Ｉ：
    Figure 2008517059
     の化合物、その立体異性体、又は薬学的に許容されるその塩を、場合により薬学的に許容される担体と組合せて含む、炎症性腸疾患を治療するための医薬組成物。
  2. 炎症性腸疾患がクローン病、潰瘍性大腸炎、非定型的大腸炎、又は感染性大腸炎である、請求項１に記載の医薬組成物。
JP2007537944A 2004-10-19 2005-10-18 炎症性腸疾患を治療するための（ｚ）−２−シアノ−３−ヒドロキシ−ブタ−２−エン酸−（４’−トリフルオロメチルフェニル）−アミドの使用 Abandoned JP2008517059A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62025504P 2004-10-19 2004-10-19
PCT/US2005/037161 WO2006044741A1 (en) 2004-10-19 2005-10-18 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease

Publications (2)

Publication Number Publication Date
JP2008517059A JP2008517059A (ja) 2008-05-22
JP2008517059A5 true JP2008517059A5 (ja) 2008-07-10

Family

ID=35636963

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007537944A Abandoned JP2008517059A (ja) 2004-10-19 2005-10-18 炎症性腸疾患を治療するための（ｚ）−２−シアノ−３−ヒドロキシ−ブタ−２−エン酸−（４’−トリフルオロメチルフェニル）−アミドの使用

Country Status (13)

Country Link
US (1) US20070197643A1 (ja)
EP (1) EP1804782A1 (ja)
JP (1) JP2008517059A (ja)
KR (1) KR20070065888A (ja)
CN (1) CN101043883A (ja)
AU (1) AU2005295511A1 (ja)
BR (1) BRPI0518205A (ja)
CA (1) CA2584655A1 (ja)
IL (1) IL182591A0 (ja)
MX (1) MX2007004265A (ja)
RU (1) RU2007118691A (ja)
SG (1) SG142305A1 (ja)
WO (1) WO2006044741A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909679B1 (en) 2005-07-11 2013-11-20 Medtronic Ablation Frontiers LLC Low power tissue ablation system
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2100881A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Pyrimidyl- or pyridinylaminobenzoic acid derivatives
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2277515A1 (en) * 2009-07-10 2011-01-26 Sanofi-Aventis Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
NZ617025A (en) * 2009-09-18 2014-03-28 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4’-trifluormethylphenyl)-amide tablet formulations with improved stability
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
MXPA00010150A (es) * 1998-04-17 2002-05-14 Parker Hughes Inst Inhibidores de btk y metodos para su identificacion y uso.
GB0005345D0 (en) * 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
CN1507354A (zh) * 2001-03-02 2004-06-23 ͨ��ҽ�ƹ�˾ 通过给予整合蛋白αvβ3拮抗剂并与其它预防或治疗药剂配合来预防或者治疗炎性疾病或自身免疫疾病的方法
EP1935416A3 (en) * 2001-04-05 2008-10-22 Aventis Pharma Inc (Z) -2-cyano-3-hydroxybut-2-enoic acid (4'-trifluoromethylphenyl) amide for the treatment of multiple sclerosis
WO2004024676A1 (de) * 2002-09-06 2004-03-25 Schebo®Biotech Ag Verbindungen zur modulation des glykolyse-enzym-und/oder transaminase-komplexes

Similar Documents

Publication Publication Date Title
JP2008517059A5 (ja)
JP2009545527A5 (ja)
JP2006515626A5 (ja)
JP2009535462A5 (ja)
JP2008513510A5 (ja)
JP2009502793A5 (ja)
JP2007522220A5 (ja)
JP2008501714A5 (ja)
JP2011518833A5 (ja)
JP2011510079A5 (ja)
JP2006526031A5 (ja)
JP2009149903A5 (ja)
JP2012107057A5 (ja)
JP2007269812A5 (ja)
JP2009536652A5 (ja)
JP2010530897A5 (ja)
JP2007302689A5 (ja)
JP2013507439A5 (ja)
JP2012514009A5 (ja)
JP2014507446A5 (ja)
JP2006503588A5 (ja)
JP2012255026A5 (ja)
JP2010501534A5 (ja)
JP2007145875A5 (ja)
JP2010536766A5 (ja)